Thromboembolism following Hip Fracture

Montrey, Jill S.; Kistner, Robert L.; A.Y., Kong,; Lindberg, Robert F.; Mayfield, Gerald W.; Jones, D. L.; Mitsunaga, Morris M.

doi:10.1097/00005373-198506000-00011

Cited by 38 publications

(15 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A number of studies have shown IPC to provide equal or slightly less DVT protection than with low-dose unfractionated heparin (LDUH) prophylaxis. 1,4,5,26,37,38,[77][78][79][80][81] Similar findings have been noted when combining prophylactic therapies such as ES and LDUH. 82,83 There is, however, no proof that the use of IPCs and/or ESs prevent PE or even proximal DVT.…”

Section: Prophylaxissupporting

confidence: 64%

Venous Thromboembolism in Trauma

2003

Semin intervent Radiol

View full text Add to dashboard Cite

The rationale of thromboprophylaxis stems from the high incidence of venous thromboembolism (VTE) in hospitalized patients, the clinically silent nature of this entity in a vast majority of patients, and the morbidity and potential mortality that can often be associated with it. There are few specific symptoms associated with deep vein thrombosis (DVT) and VTE, thus making clinical diagnosis unreliable. Making appropriate diagnosis and implementing treatment of DVT prior to a potentially fatal embolic event or the potential sequelae and long-term morbidity of the postphlebitic syndrome is a difficult task in any hospitalized patient. In the setting of trauma, however, diagnosis, prevention, and treatment of DVT and VTE become much more difficult.Objectives: Upon completion of this article, the reader will understand the pathophysiology, diagnosis, and treatment options concerning venous thromboembolic disease. Accreditation: Tufts University School of Medicine (TUSM) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. TUSM takes responsibility for the content, quality, and scientific integrity of this CME activity. Credit: TUSM designates this educational activity for a maximum of 1 Category 1 credit toward the AMA Physicians Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

show abstract

Section: Prophylaxissupporting

confidence: 64%

Venous Thromboembolism in Trauma

2003

Semin intervent Radiol

View full text Add to dashboard Cite

show abstract

“…An autopsy study 49 reported an incidence of deep venous thrombosis of 83%. Studies using routine venography give incidences of 19-91% 50,51,52 and between 10-14% for pulmonary embolism when routine isotope lung scans are used 53 . Summation of studies which report on the incidence as diagnosed in clinical practice, give rates of venous thrombosis of about 3% and pulmonary embolism of about 1%.…”

Section: Key Pointmentioning

confidence: 99%

Nontraumatic Emergency Laparotomy: Surgical Principles Similar to Trauma Need to Be Adopted?

Singh-Ranger

Leung

Lau-Robinson

et al. 2017

Southern Medical Journal

View full text Add to dashboard Cite

show abstract

“…Eight patients died during the study period. The (1)(2)(3)(4)(5)(6)(7)(8), but no study has been conducted with the aim of evaluating preoperative thromboprophylaxis. One study (8) applying preoperative phlebography proved 12% of patients developed DVT preoperatively.…”

mentioning

confidence: 99%

Early Preoperative Thromboprophylaxis with Klexane® in Hip Fracture Surgery: A Placebo-Controlled Study

Jørgensen

Strandberg

Wille‐Jørgensen

et al. 1998

Clin Appl Thromb Hemost

View full text Add to dashboard Cite

The aim of this study was to evaluate any possible benefits of early thromboprophylactic treatment in the prevention of deep vein thrombosis (DVT) in high-risk hip fracture patients. Within 30 months, 239 patients were included in a double-blind placebo-controlled study. With the diagnosis of hip fracture confirmed, patients received either 40-mg Enoxaparin s.c. or placebo once daily until operation. Postoperatively, all patients received 40-mg Enoxaparin s.c. once daily until phlebography. Phlebography was first performed on the operated leg, and with no thrombosis detected, the other leg was investigated as well. The two groups did not differ demograph-ically. Eighty-five patients were excluded. Eight patients died during the study period. The remaining 146 patients had ascending phlebography performed and 24 patients (16.4%) developed DVT. Nine (12%) of 75 patients in the Klexane® and 15 (21 %) of 72 patients in the placebo group developed DVT.The risk ratio was 0.58 (95% confidence limits 0.27-1.25) and p = .15 (X2 test). There was no difference in perioperative bleeding or transfusion requirements. We conclude that Klex-ane® is an effective and safe thromboprophylactic agent in hip fracture patients.

show abstract

Thromboembolism following Hip Fracture

Cited by 38 publications

References 0 publications

Venous Thromboembolism in Trauma

Venous Thromboembolism in Trauma

Nontraumatic Emergency Laparotomy: Surgical Principles Similar to Trauma Need to Be Adopted?

Early Preoperative Thromboprophylaxis with Klexane® in Hip Fracture Surgery: A Placebo-Controlled Study

Contact Info

Product

Resources

About